Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) received a $86.00 price target from investment analysts at Jefferies Group in a note issued to investors on Wednesday. The firm currently has a a “buy” rating on the biopharmaceutical company’s stock. Jefferies Group’s target price points to a potential upside of 12.17% from the company’s previous close.
A number of other equities research analysts have also recently weighed in on the company. FBR & Co reaffirmed an “outperform” rating and set a $180.00 price target on shares of Alnylam Pharmaceuticals in a report on Sunday, July 17th. Zacks Investment Research cut Alnylam Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, July 25th. Morgan Stanley initiated coverage on Alnylam Pharmaceuticals in a research note on Tuesday, August 2nd. They issued an “overweight” rating and a $93.00 target price for the company. Needham & Company LLC reissued a “buy” rating and issued a $152.00 target price on shares of Alnylam Pharmaceuticals in a research note on Friday, July 1st. Finally, Cowen and Company reissued a “buy” rating and issued a $150.00 target price on shares of Alnylam Pharmaceuticals in a research note on Sunday, August 7th. Three investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $110.79.
Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) traded down 7.76% during midday trading on Wednesday, reaching $70.72. The company had a trading volume of 978,367 shares. The company’s 50-day moving average is $73.60 and its 200-day moving average is $66.18. Alnylam Pharmaceuticals has a 52-week low of $49.96 and a 52-week high of $110.75. The firm’s market cap is $6.06 billion.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($1.05) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($1.24) by $0.19. Alnylam Pharmaceuticals had a negative return on equity of 29.60% and a negative net margin of 1,204.91%. The firm earned $8.70 million during the quarter, compared to analysts’ expectations of $8.09 million. During the same period last year, the firm posted ($0.85) EPS. The business’s revenue was up .2% on a year-over-year basis. Equities research analysts expect that Alnylam Pharmaceuticals will post ($4.64) EPS for the current fiscal year.
In other news, CEO John Maraganore sold 30,151 shares of the business’s stock in a transaction dated Wednesday, July 20th. The stock was sold at an average price of $64.69, for a total value of $1,950,468.19. Following the sale, the chief executive officer now directly owns 148,465 shares in the company, valued at $9,604,200.85. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 4.00% of the stock is owned by insiders.
Several hedge funds have recently modified their holdings of the stock. Norges Bank purchased a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth approximately $56,311,000. Fjarde AP Fonden Fourth Swedish National Pension Fund raised its stake in shares of Alnylam Pharmaceuticals by 8.8% in the first quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 23,473 shares of the biopharmaceutical company’s stock worth $1,473,000 after buying an additional 1,892 shares during the period. Aperio Group LLC raised its stake in shares of Alnylam Pharmaceuticals by 129.9% in the first quarter. Aperio Group LLC now owns 14,741 shares of the biopharmaceutical company’s stock worth $925,000 after buying an additional 8,328 shares during the period. Parametrica Management Ltd purchased a new stake in shares of Alnylam Pharmaceuticals during the first quarter worth approximately $205,000. Finally, Pacad Investment Ltd. purchased a new stake in shares of Alnylam Pharmaceuticals during the first quarter worth approximately $490,000. Institutional investors own 85.96% of the company’s stock.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). It is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines; Cardio-Metabolic Disease, and Hepatic Infectious Disease.
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.